Introduction of KRAS

RAS is a family of GTPase proto-oncogenes, comprising three closely related RAS isoforms: HRAS, KRAS and NRAS.

From all of the RAS isoforms, KRAS is most frequently mutated.

KRAS mutations are particularly frequent in the pancreatic, lung and colorectal cancers.

KRAS gene is a proto-oncogene that encodes a GTP/GDP-binding protein that belongs to the GTPase RAS family.

The KRAS protein acts as molecular switchs that cycle between a GDP-bound inactive state and a GTP-bound active state.

KRAS protein switches between an inactive to an active form via binding to GTP and GDP, respectively.

• 
  KRAS-targeted Drugs R&D Service
  KRAS-targeted Drugs R&D Service

  In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.